Profile
CASI VRTX REGN VRNA ARGX ALNY
Company Name CASI Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $15.34M $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.23K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO David A. Cory Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
CASI VRTX REGN VRNA ARGX ALNY
Quant Rating Score 2 4 4 1 4 3
Quant Rating Sell Buy Buy Strong Sell Buy Neutral
Trading
CASI VRTX REGN VRNA ARGX ALNY
Last Close $1.19 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $5.34 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $1.19 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -77.72 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 0 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
CASI VRTX REGN VRNA ARGX ALNY
1 Month Return -31.61 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return -47.35 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return -38.69 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return -52.87 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return -57.95 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return -77.72 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CASI VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
CASI VRTX REGN VRNA ARGX ALNY
Asset Growth -28.69 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth -44.41 % 1.16 % - 26.81 %
Revenue Growth -15.77 % 0.99 % - 22.97 %
Revenue 3 Year -16.07 % 20.64 % -15.89 % 147.1 %
Revenue 5 Year 332.08 % 73.64 % - 775.72 %
Revenue 10 Year 22320.04 % 285.02 % - 2487.4 %
EBIT Growth -47.14 % 9.09 % -131.37 % 24.59 %
Net Income Growth -45.73 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share 4.97 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share 45.87 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share 72.07 % 680.22 % -35.51 % 55.09 %
Operating Income Growth -57.98 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) -46.36 % - -143.33 % -107.98 %
Operating 3 Year CFG 3.4 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG 21.36 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG -36.35 % -100 % 40.15 % 97.08 %
EPS Growth -26.73 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth -26.73 % 8.19 % -208.93 % 38.07 %
Book Value Per Share -93.33 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share -98.06 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share -98.41 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share 181.72 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth -15.27 % - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth 4.25 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth -32.67 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
CASI VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM 35.8 % 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -201.86 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM 358.32 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM 301.46 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 104.61 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 104.68 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM -167.98 % 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM - 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM 10.29 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM 30.78 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM 6.6 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM 269.89 % 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM 109.75 % 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM - 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM - 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 29.19 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM - 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM - 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM - 36.72 20 -995.27 128.45 195.85
Price To Operating Cash Flows Ratio TTM - 32.86 16.23 -126.33 145.01 162.25
Price Cash Flow Ratio TTM - 32.86 16.23 -126.33 145.01 162.25
Income Statement (TTM)
CASI VRTX REGN VRNA ARGX ALNY
Revenue $0.03B $11.02B $14.34B $0.03B $2.19B $2.25B
Gross Profit $0.01B $9.49B $12.24B $0.03B $1.96B $1.92B
Gross Profit Ratio 39.06% 86.11% 85.35% 93.89% 89.62% 85.62%
EBITDA $-0.03B $0.49B $5.82B $-0.12B $0.11B $-0.18B
Net Income $-0.04B $-0.54B $4.5B $-0.14B $0.83B $-0.28B
EPS Diluted -2.56 -2.08 41.48 -1.73 12.78 -2.18
Balance Sheet (MRQ)
CASI VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.71B $0.12B $0.03B $2.59B
Total Liabilities $0.05B $6.12B $9.3B $0.27B $0.7B $4.17B
Total Equity $0B $16.41B $31.26B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $16.08B $0.02B $1.93B $1.73B
Total Debt $0.02B $1.75B $2.71B $0.12B $0.04B $2.74B
Total Assets $0.05B $22.53B $40.56B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
CASI VRTX REGN VRNA ARGX ALNY
Net Income $-0.04B $-0.54B $4.5B $-0.17B $0.83B $-0.28B
Inventory $0.01B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $-0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.03B $-0.49B $4.98B $-0.12B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.9B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.52
AARD Aardvark Therapeutics, Inc. Common Stock 12.65
ABCL AbCellera Biologics Inc. 3.16
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.13
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.4
ABPWW 0.0155
ABSI Absci Corporation 2.695
ABUS Arbutus Biopharma Corporation 3.84
ABVC ABVC BioPharma, Inc. 1.74
ABVX Abivax SA American Depositary Shares 117.67
ACAD ACADIA Pharmaceuticals Inc. 23.56
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.03
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.25
ACIU AC Immune SA 3.14
ETFs With Exposure to CASI
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 340.96
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 151.14
CHNA Loncar China BioPharma ETF 0.5 13.53
PQSG PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF 0.18 72.5283
DFAU Dimensional US Core Equity Market ETF 0.000002 47.92
JKK iShares Morningstar Small-Cap Growth ETF 0.01 307.42
JKJ iShares Morningstar Small-Cap ETF 0 231.193
Unlock